IGM Biosciences, Inc. (NASDAQ:IGMS) was down 6.5% during trading on Wednesday following insider selling activity. The stock traded as low as $62.08 and last traded at $62.08. Approximately 1,275 shares changed hands during mid-day trading, a decline of 99% from the average daily volume of 165,511 shares. The stock had previously closed at $66.39.Specifically, insider Bruce Keyt sold 1,242 shares of IGM Biosciences stock in a transaction that occurred on Tuesday, October 5th. The shares were sold at an average price of $64.10, for a total transaction of $79,612.20. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Julie Hambleton sold 1,000 shares of IGM Biosciences stock in a transaction that occurred on Monday, August 9th. The shares were sold at an average price of $80.00, for a total transaction of $80,000.00. The disclosure for this sale can be found here. Insiders sold a total of 4,728 shares of company stock valued at $330,765 over the last 90 days. Corporate insiders own 61.92% of the company's stock.
A number of equities research analysts have weighed in on IGMS shares. Wedbush boosted their target price on shares of IGM Biosciences from $77.00 to $82.00 and gave the stock a "neutral" rating in a report on Monday, August 16th. They noted that the move was a valuation call. Morgan Stanley assumed coverage on shares of IGM Biosciences in a report on Thursday, August 26th. They set an "overweight" rating and a $100.00 price objective on the stock. HC Wainwright restated a "buy" rating and set a $114.00 price objective on shares of IGM Biosciences in a report on Tuesday, August 10th. Finally, Zacks Investment Research upgraded shares of IGM Biosciences from a "sell" rating to a "hold" rating in a report on Tuesday, August 31st. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, IGM Biosciences presently has an average rating of "Buy" and a consensus price target of $104.00.
The company has a market cap of $2.00 billion, a P/E ratio of -17.56 and a beta of -1.04. The company's 50-day moving average is $72.89 and its two-hundred day moving average is $75.63.
IGM Biosciences (NASDAQ:IGMS) last posted its quarterly earnings results on Sunday, August 8th. The company reported ($1.16) earnings per share for the quarter, meeting the Thomson Reuters' consensus estimate of ($1.16). As a group, sell-side analysts forecast that IGM Biosciences, Inc. will post -5.03 EPS for the current fiscal year.
A number of large investors have recently modified their holdings of IGMS. Macquarie Group Ltd. boosted its position in IGM Biosciences by 313.6% during the second quarter. Macquarie Group Ltd. now owns 579 shares of the company's stock worth $48,000 after purchasing an additional 439 shares during the period. Nisa Investment Advisors LLC bought a new position in IGM Biosciences during the second quarter worth about $50,000. Legal & General Group Plc boosted its position in IGM Biosciences by 16.4% during the second quarter. Legal & General Group Plc now owns 1,336 shares of the company's stock worth $112,000 after purchasing an additional 188 shares during the period. E Fund Management Co. Ltd. bought a new position in IGM Biosciences during the first quarter worth about $121,000. Finally, Metropolitan Life Insurance Co NY boosted its position in IGM Biosciences by 115,000.0% during the second quarter. Metropolitan Life Insurance Co NY now owns 2,302 shares of the company's stock worth $192,000 after purchasing an additional 2,300 shares during the period. Hedge funds and other institutional investors own 50.86% of the company's stock.
About IGM Biosciences (NASDAQ:IGMS)
IGM Biosciences, Inc, a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of multiple diseases. Its lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 1 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL).
Recommended Story: Trade Deficit
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Before you consider IGM Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IGM Biosciences wasn't on the list.
While IGM Biosciences currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The 5 Stocks Here